Preventive Vaccines Market Size, Share, By Vaccine Type (Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, Recombinant Vector Vaccines, and DNA Vaccines), Disease Type (Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Mumps and Rubella (MMR), Varicella, Human Papilloma Virus, and Others), Distribution Channel (Public and Private), and Region - Trends, Analysis, and Forecast till 2035

Preventive vaccines market size was valued at USD 91.6 Billion in 2025 and is expected to reach USD 112.2 Billion by 2035, growing at a CAGR of 2.2%

Preventive vaccines aim to increase the immune system's ability to recognize and fight off certain infections (bacteria or viruses) before it causes illness, hence preventing disease. The market for preventive vaccines is growing due to its significance in disease prevention, its capacity to lessen the severity of illness, its affordability, its capacity to lower antibiotic resistance, its ability to eradicate disease, and its advantages for people of all ages, from young children to elderly people.

The preventive vaccines market is expanding due to a number of factors, including the proliferation of infectious diseases, the aging population, government immunization programs and policies, technological advancements in vaccine development, increased funding and investment in R&D, the rise in emerging infectious diseases, the expansion of cold chain infrastructure, and the growing adoption of combination vaccines. Further factors propelling the target market growth include the development of personalized and therapeutic vaccines, the integration of big data and artificial intelligence in vaccine development, the expansion of universal immunization programs, and robust partnerships and investments among pharmaceutical companies, governments, and non-profits.